This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Preview: Inogen (INGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inogen (INGN) Down 6.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Earnings Miss Estimates in Q1, View Lowered
by Zacks Equity Research
Inogen (INGN) slashes revenue and net income guidance for 2019.
Inogen (INGN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Inogen's (INGN) first-quarter 2019 results are expected to get a boost from product launches.
Why the Earnings Surprise Streak Could Continue for Inogen (INGN)
by Zacks Equity Research
Inogen (INGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inogen (INGN) Launches One G5 Portable Oxygen Concentrator
by Zacks Equity Research
Inogen's (INGN) product launch is in line with the company's strategy of providing innovative and long-term oxygen therapy to patients in need of respiratory aid.
Inogen (INGN) Down 12.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bull of the Day: DexCom (DXCM)
by Kevin Cook
Diabetes care goes beyond the finger prick to streaming digital data with this rapidly growing innovator
Inogen's Prospects in Europe Solid Amid Trade-Related Tension
by Zacks Equity Research
Inogen's (INGN) business-to-business unit sees strength in Europe.
Inogen (INGN) Q4 Earnings Beat Estimates, Rental Revenues Up
by Zacks Equity Research
Inogen (INGN) gains from solid direct-to-consumer revenues in Q4; strong business-to-business revenues in the United States.
Inogen Gains From Commercial Launch of Wireless Connect
by Zacks Equity Research
Inogen's (INGN) expanding product portfolio lends it a competitive edge in the respiratory care devices market.
Why Is Inogen (INGN) Down 7.9% Since Last Earnings Report?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Q3 Earnings Beat, 2018 Revenue Guidance Up
by Zacks Equity Research
Inogen (INGN) gains from solid direct-to-consumer revenues in Q3; 2018 view up.
Omnicell (OMCL) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Inogen (INGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (INGN) Outperforming Other Medical Stocks This Year?
Inogen (INGN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 40.38% and 4.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Top Stock Picks for the Week of November 5th
by Panel Of Zacks Experts
Two Companies Outperforming Their Industries.
Can Solid European Sales Boost Inogen (INGN) in Q3 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in the third quarter. However, the decline in rental revenues is a concern.
Integra (IART) Q3 Earnings Meet Estimates, Revenue View Dips
by Zacks Equity Research
Integra LifeSciences' (IART) success with its channel expansion policy and Codman acquisition raise optimism on the stock.
Inogen (INGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Inogen (INGN) closed the most recent trading day at $192.30, moving +0.6% from the previous trading session.
NuVasive (NUVA) Q3 Earnings Lag Estimates, Revenues Top Mark
by Zacks Equity Research
NuVasive (NUVA) registers balanced growth across its couple of business wings.
Chemed (CHE) Beats on Q3 Earnings, Raises 2018 Guidance
by Zacks Equity Research
The expansion in adjusted operating margin at Chemed (CHE) raises investor hopes on the stock.
Inogen (INGN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerner's (CERN) Q3 Earnings Match Estimates, Bookings Up Y/Y
by Zacks Equity Research
Cerner (CERN) gains from strong segmental revenues in the third quarter. Guidance for 2018 is impressive.